Kidney transplant outcomes in patients 65 and older
Part of Bones, joints & muscles, Infections clinical trials.
This study observes older kidney transplant patients (65+) who take a specific anti-rejection drug called tacrolimus once a day. It looks at their long-term outcomes to help improve care for people in this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years of age or older.
- You have received a kidney transplant.
- You are taking tacrolimus once a day (Advagraf) along with mycophenolate and steroids.
- Your transplant came from a donor with a compatible blood type.
- You do not have donor-specific antibodies (DSA) and your PRA is 20% or lower.
- You have not had more than two kidney transplants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This study tests whether some older adults who have had a kidney transplant for more than a year can safely stop taking one of their anti-rejection medicines (mycophenolate mofetil, or MMF) instead of staying on it long-term. If you qualify, you may be able to reduce your daily pill burden while keeping your new kidney safe.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
This study tests if switching to an extended-release form of your anti-rejection medication (tacrolimus) helps protect memory and thinking skills. It is for older adults who have had a kidney transplant at least one year ago.
This trial tests whether older kidney transplant recipients can safely reduce their immunosuppression medications using a special monitoring tool called Trugraf. If you are over 55, have had a stable transplant, and want to possibly lower your medications, this study may be for you.
Hear when a new Graft Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.